Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY) will announce quarterly loss of $0.75 per share in its forthcoming report, representing an increase of 46.4$421.1 million, increasing 31.9% from the same quarter last year. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during ...